ACAD
ACADIA Pharmaceuticals Inc
NASDAQ: ACAD · HEALTHCARE · BIOTECHNOLOGY
$27.83
+0.32% today
Updated 2026-09-11
Market cap
$4.77B
P/E ratio
12.36
P/S ratio
4.19x
EPS (TTM)
$2.24
Dividend yield
—
52W range
$20 – $31
Volume
1.6M
WallStSmart proprietary scores
61
out of 100
Grade: C+
Hold
Investment rating
8.0
Growth
A8.5
Quality
A8.0
Profitability
A5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$34.00
+22.17%
12-Month target
$21.13
-24.07%
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy12 Buy4 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 33.40% — above average
+ ROE 30.10% — strong efficiency
+ Free cash flow $124.46M — positive
+ Revenue growth 16.40% QoQ
+ Debt/equity 0.06x — low leverage
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $517.24M | $726.44M | $957.80M | $1.07B | $1.14B |
| Net income | $-215.97M | $-61.29M | $226.45M | $391.00M | $31.50M |
| EPS | — | — | — | — | $2.24 |
| Free cash flow | $-114.03M | $-23.35M | $157.20M | $105.15M | $124.46M |
| Profit margin | -41.76% | -8.44% | 23.64% | 36.49% | 33.40% |
Peer comparison
Smart narrative
ACADIA Pharmaceuticals Inc trades at $27.83. representing a P/E of 12.36x trailing earnings. Our Smart Value Score of 61/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.14, it sits in the grey zone. TTM revenue stands at $1.14B. with profit margins at 33.40%.
Frequently asked questions
What is ACADIA Pharmaceuticals Inc's stock price?
ACADIA Pharmaceuticals Inc (ACAD) trades at $27.83, on a P/E of 12.4x and a P/S of 4.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is ACADIA Pharmaceuticals Inc overvalued?
ACADIA Pharmaceuticals Inc carries a Smart Value Score of 61/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read.
What is the price target of ACADIA Pharmaceuticals Inc (ACAD)?
The 12-month analyst consensus target is $34.00, about 22.2% above the current $27.83. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is ACADIA Pharmaceuticals Inc's revenue?
ACADIA Pharmaceuticals Inc's trailing twelve-month revenue is $1.14B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
ACADIA Pharmaceuticals Inc's Altman Z-Score is 2.14, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio4.19x
ROE30.10%
Beta0.86
50D MA$27.38
200D MA$24.51
Shares out0.17B
Float0.13B
Short ratio—
Avg volume1.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—